PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that it has entered into an exclusive distribution agreement with China Bao Tai Investment Company, Ltd., for the rights to its Microcyn®-based wound care solution in China. The non-irritating, oxychlorine compound technology, which is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores, will be packaged under China Bao Tai’s private label brand names in China. The five-year agreement provides for minimum purchases of $12 million of Oculus’ Microcyn Technology.
